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Purpose
With the emergence of next-generation sequencing (NGS) technology, profiling a wide range
of genomic alterations has become a possibility resulting in improved implementation of
targeted cancer therapy. In Asian populations, the prevalence and spectrum of clinically 
actionable genetic alterations has not yet been determined because of a lack of studies 
examining high-throughput cancer genomic data.  
Materials and Methods
To address this issue, 1,071 tumor samples were collected from five major cancer institutes
in Korea and analyzed using targeted NGS at a centralized laboratory. Samples were either
fresh frozen or formalin-fixed, paraffin embedded (FFPE) and the quality and yield of extracted
genomic DNA was assessed. In order to estimate the effect of sample condition on the quality
of sequencing results, tissue preparation method, specimen type (resected or biopsied) and
tissue storage time were compared. 
Results
We detected 7,360 non-synonymous point mutations, 1,164 small insertions and deletions,
3,173 copy number alterations, and 462 structural variants. Fifty-four percent of tumors
had one or more clinically relevant genetic mutation. The distribution of actionable variants
was variable among different genes. Fresh frozen tissues, surgically resected specimens,
and recently obtained specimens generated superior sequencing results over FFPE tissues,
biopsied specimens, and tissues with long storage duration.   
Conclusion
In order to overcome, challenges involved in bringing NGS testing into routine clinical use,
a centralized laboratory model was designed that could improve the NGS workflows, provide
appropriate turnaround times and control costs with goal of enabling precision medicine.
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Introduction
During the past decade, the emergence of next-generation
sequencing (NGS) technologies has made comprehensive
and highly sensitive analysis of cancer genomes feasible [1].
In addition to providing important insights into the molecu-
lar events involved in tumorigenesis, these technological 
advances offer great benefits to patients by improving diag-
nostic accuracy, identifying prognostic biomarkers and 
increasing utilization of targeted therapies [2,3]. Many NGS-
based projects, including the Cancer Genome Atlas (TCGA)
studies, have been able to identify a wide range of clinically
relevant genomic alterations within multiple cancer types [4].
These molecular profiling efforts have been essential to the
development of targeted therapies leading to more person-
alized cancer management. In addition, many clinical trials
are now utilizing deep sequencing to randomize, cancer 
patients to new genomically-matched treatments [2,5]. While
comprehensive molecular profiling of tumors has become 
increasingly important, there is a limited amount of high-
throughput genomic data in East-Asian populations. Conse-
quently, it has been difficult to estimate the frequency of clin-
ically actionable mutations in Korea [2,6]. 
The National Health Insurance Service of Korea now 
includes NGS testing in its insurance coverage (S1 Table).
While NGS tests have become more affordable, there are still
challenges involved in bringing these tests into routine clin-
ical practice in Korea. First, significant investments are 
required to build and maintain the computational infrastruc-
ture that enables genomic testing and research [7]. Second,
bioinformatics specialists and server engineers are required
to run the sophisticated software and manage scientific com-
puting. These resource-intensive prerequisites surpass the
capacity of smallest laboratories and impose significant chal-
lenges even for large cancer centers [8]. In light of such 
issues, we propose a new centralized laboratory model that
could ensure accessibility and sustainability of NGS tests for
providers. Local cancer centers would send their tumor tis-
sue samples to a central sequencing and bioinformatics hub
and have them analyzed within a reasonable turnaround
time at a fraction of the cost (Fig. 1) [8].
In this study, we collected over 1,071 tumor samples, (598
lung cancers, 197 stomach cancers, 107 colorectal cancers
[CRCs], 69 breast cancers, and 100 other cancer types includ-
ing ovarian, head and neck, thymic, melanoma, and esopha-
geal), from five major cancer centers in Korea and used a
high-depth targeted sequencing panel to sequence genomic
DNA samples. We comprehensively profiled genetic alter-
ations in patients with advanced cancer and evaluated the
clinical utility of NGS technology. Here, we present the 
genomic landscape of common cancers in Korea and defines
potential driver mutations that may affect clinical decision
making. Furthermore, we share our experience serving as a
centralized laboratory for five major cancer centers in Korea.
A thorough analysis of specimen types with respect to DNA
yield and DNA fragment size helped optimize our NGS
workflow. The ultimate goal is to advance the implementa-
tion and adoption of NGS in Korea as a critical component
for improving patient outcomes through the practice of pre-
cision medicine. 
Materials and Methods
1. Patient samples
We collected 1,071 tumor samples from 993 patients from
five major Korean medical institutes. Specimens were pre-
pared from fresh frozen (FF) tissue (n=323) or formalin-fixed
and paraffin embedded (FFPE) tissue (n=748). Following 
microscopic examination of hematoxylin and eosin-stained
slides, macrodissection was performed to enrich for tumor
cells as needed. For DNA extraction, 10 tissue slides, 5 µm,
were required for small biopsy samples whereas 2-5 slides,
5 µm, were needed for resected specimens. Genomic DNA
from FFPE tissues was extracted using the Qiagen DNA
FFPE Tissue kit (Qiagen, Valencia, CA), and DNA from FF
tissues was extracted using the QIAamp DNA mini kit (Qia-
gen). DNA yield was evaluated using a Nanodrop 8000 
UV-Vis spectrometer (NanoDrop Technologies Inc., Wilm-
ington, DE) and Qubit 3.0 Fluorometer (Thermo Fisher Sci-
entific, Waltham, MA). DNA size was examined using a 2200
TapeStation Instrument (Aglient Technologies, Santa Clara,
CA). Specimens with a DNA yield over 100 ng and a median
DNA fragment size of at least 350 bp were selected for tar-
geted sequencing. 
2. Targeted sequencing and bioinformatics
Targeted sequencing was performed using the Cancer-
SCAN [9] panel which includes the whole exomes of 375 can-
cer-related genes and the intronic regions of 23 genes.
Genomic DNA was sheared using a Covaris S220 (Covaris,
Woburn, MA). Target capture was performed using the Sure-
Select XT Reagent Kit, HSQ (Agilent Technologies) and a
paired-end sequencing library was constructed with a bar-
code. Sequencing was performed on a HiSeq 2500 with 100-
bp reads (Illumina, San Diego, CA). One hundred samples
were able to be sequenced in a single experiment when using
high throughput mode and 17 samples were able to be 
sequenced when using fast mode.
212 CANCER  RESEARCH  AND  TREATMENT
Se-Hoon Lee, Korean Landscape of Actionable Genetic Alterations
Fi
g. 
1. 
 D
iag
ra
m
 of
 ce
nt
ra
l la
b m
od
el.
 Sa
m
pl
es
 ar
e c
oll
ec
ted
 to
 a 
ce
nt
ra
l la
b a
nd
 pr
oc
es
se
d 
us
in
g t
he
 sa
m
e p
lat
fo
rm
 so
 th
e r
es
ul
tin
g d
ata
 ca
n b
e e
as
ily
 in
teg
ra
ted
.
At
 a 
ce
nt
ra
l la
bo
ra
to
ry
, s
am
pl
e p
re
pa
ra
tio
n p
ro
ce
du
re
s, 
in
clu
di
ng
 qu
ali
ty
 co
nt
ro
l, s
eq
ue
nc
in
g, 
an
d d
ata
 an
aly
sis
, w
er
e p
er
fo
rm
ed
. In
 th
is 
pr
oje
ct,
 fiv
e t
er
tia
ry
 ho
s-
pi
tal
s w
er
e p
ar
tic
ip
ati
ng
. F
F, 
fre
sh
 fr
oz
en
; F
FP
E, 
fo
rm
ali
n-
fix
ed
, p
ar
aff
in
 em
be
dd
ed
.
50(%
) 010203040
St
om
ac
h
PIK3CA
KRAS
ERBB2
FGFR2
CDK6
AKT1
CDK4
BRAF
EGFR
MET
KIT
NRAS
CTNNB1
MDM2
50(%
) 010203040
CR
C
KRAS
PIK3CA
ERBB2
MTOR
NTRK1
NRAS
BRAF
Am
pl
ifi
ca
tio
n
Fu
sio
n
No
n-
sy
no
ny
m
ou
s
50(%
) 010203040
Br
ea
st
PIK3CA
ERBB2
ESR1
In
te
gr
at
in
g 
da
ta
 
Da
ta
 m
in
in
g 
&
 a
na
ly
si
s
Ce
nt
ra
l l
ab
Ca
nc
er
 c
en
te
rs
Re
po
rts
 fo
r
ac
tio
na
bl
e
m
ut
at
io
ns
Sa
m
pl
es
FF
 o
r F
FP
E
Sa
m
pl
e 
pr
ep
qu
al
ity
 c
on
tro
l
Hi
gh
 th
ro
ug
hp
ut
se
qu
en
ci
ng
Bi
oi
nf
or
m
at
ic
s
an
al
ys
is
Lu
ng
St
om
ac
h
Co
lo
n
Br
ea
st
et
c
VOLUME 51 NUMBER 1 JANUARY 2019  213
Cancer Res Treat. 2019;51(1):211-222
The paired-end reads were aligned to the human reference
genome (hg19) using BWA-MEM v0.7.5. Samtools v0.1.18,
GATK v3.1-1, and Picard v1.93 were used for bam file han-
dling, local realignment, and removal of duplicate reads, 
respectively. Samples with a mean target coverage of less
than 200 were excluded from further analysis. Single 
nucleotide variants (SNVs) with a variant allele fraction
greater than 1% were detected using MuTect v1.1.4, and
Lowfreq v0.6.1. Sequencing errors were filtered out by an 
in-house algorithm using data extracted from each bam file.
Insertions and deletions (indels) that were less than 30 bp in
size were detected using Pindel v0.2.5a4. Possible germline
polymorphisms were also filtered out if the allele frequency
was more than 0.1% in any of the normal population data-
bases including the: 1000 Genomes Project database, The
Exome Aggregation Consortium (ExAC) database, the Natio-
nal Heart, Lung and Blood Exome Sequencing Project (ESP)
database, the Korean Reference Genome Database, or the 
Korean Variant Archive (KOVA) [10]. Structural variants
(SVs) and large indels (> 30 bp) were detected using an 
in-house SV caller. Copy number alterations (CNAs) of each
gene were also detected using an in-house copy number
caller with copy numbers greater than 6 being marked as 
amplifications and a copy numbers less than 0.7 designated
as deletions.
3. Actionable alterations 
We defined actionable alterations as SNVs, indels, CNAs,
or SVs with the potential to affect clinical decisions or impact
the way patients are enrolled in clinical trials. Detected DNA
alterations were annotated by an in-house database created
for CancerSCAN [9]. SNVs were matched with the database
for amino acid level change, indels were matched with the
database at the exon level change, and CNAs and SVs were
matched with changes at the gene level.
4. Statistical analysis
Statistical analysis was conducted using the R v3.3.2. A chi-
square test was used to determine the association between
two categorical variables, a T-test was used to examine the
association between one categorical variable and one contin-
uous variable, and a Pearson’s correlation test was used to
evaluate the association between two continuous variables.
Firth’s bias-reduced logistic regression was determined
using the logistf R package v1.22 to assess the effect of each
variable on the success of sequencing. Following this, an
odds ratio (OR) was calculated for each variable. Signifi-
cantly mutated genes were identified using MutSigCV v1.41.
Genes with a significant CNA were identified using GISTIC
v2.0.23. A p-value less than 0.05 was considered significant
and genes with a false discovery rate (q-value) less than 0.1
were considered to be significantly mutated genes—either
significantly amplified or significantly deleted.
5. Ethical statement
The study was approved by the Institutional Review Board
of Samsung Medical Center, Seoul, Korea (SMC-2016-
03-094), Severance Hospital, Seoul, Korea (4-2016-0135),
Seoul St. Mary’s Hospital, Seoul, Korea (2016939), Asan Med-
ical Center, Seoul, Korea (S2016-0498-0007), and Seoul 
National University Hospital, Seoul Korea (H-1606-076-771).
Some patients provided written informed consent for this
study. Some patients provided written informed consent for
other study and agreed secondary uses of data. Consent was
waived for the other patients. 
Results
1. Sample information 
A total of 1,071 cancer samples of various types were col-
lected from five different institutes: 598 lung cancers, 197
stomach cancers, 107 CRCs, 69 breast cancers, and 100 other
cancer types including ovarian, head and neck, thymic,
melanoma, and esophageal (S2 Table). Of the 598 lung cancer
samples, 525 were non-small cell lung cancer (NSCLC) and
73 were small cell lung cancer (SCLC). NSCLC samples made
up a high proportion (49%) of the samples in this study. Of
the study samples, 493 were obtained by biopsy, 499 were
obtained by surgical resection, and 79 were obtained from
other methods. A total of 323 samples were FF tissue, and
748 samples were FFPE tissue. The median storage duration
from tissue sampling to DNA extraction was 313 days (range,
1 to 6,018 days). In total, 224 samples (21%) were excluded
due to low quality. This included 153 (14%) samples with a
DNA yield less than or near 100 ng and 12 samples (1%) with
a median DNA fragment size less than 350 bp that were 
excluded prior to sequencing (S3 Table). In addition, 59 sam-
ples (6%) with a mean target coverage less than 200 were 
excluded from the analysis. Some samples were obtained
from different (primary or metastatic) sites of the same 
patient. The result from one sample is used per patients
when analyzing mutation landscape.
Sequencing results from 803 patient specimens were 
included in the analysis. NGS detected 7,360 non-synony-
mous SNVs, 1,164 indels, 3,173 CNAs, and 462 SVs. Tumor
mutational burden was calculated for each tumor type 
cohort. The median number of SNVs per megabase DNA
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Fig. 2.  The effect of sample condition on extracted DNA size. (A) In formalin-fixed, paraffin embedded (FFPE) samples, the
size of DNA was shorter with degradation. This phenomenon was more prominent in resected tissues than in biopsied tis-
sues. The horizontal line at 350 bp represented the minimum required size of extracted DNA to be included in the sequencing
step. (B) The size of DNA tended to be shorter as storage duration prolonged. The horizontal line at 350 bp represented the
minimum required size of extracted DNA to be included in the sequencing step. FF, fresh frozen; NSCLC, non-small cell
lung cancer; SCLC, small cell lung cancer.
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within NSCLC, SCLC, stomach cancer, CRC, and breast can-
cer were 10.7, 14.2, 11.5, 12.3, and 11.1, respectively (S4 Fig.).
The median number of small indels was 1 or 2 per megabase
of DNA within each cancer types. More CNAs were present
in SCLC and breast cancer than the other cancer types. For
tested genes, the median number of genes with an altered
copy number was 1.4% for SCLC and 1.1% for breast cancer. 
2. Test quality  
To estimate the effect of sample condition on the test qual-
ity, statistical analyses were performed for the tissue prepa-
ration method, specimen type (resected or biopsied sample),
cancer type, and tissue storage time. As sufficient DNA yield
and fragment size were the primary prerequisites for the
analysis, the association between sample condition and DNA
yield and that between sample condition and DNA size were
examined. DNA yield was found to be affected by the tissue
preparation method, specimen type, and cancer type 
(S5 Table). Median DNA fragment size was found to be 
affected by the tissue preparation method and cancer type
(S6 Table). 
It is known that FFPE tissue experiences DNA degradation
during storage [11]. Thus, we further examined the effect of
sample condition on DNA fragment size (Fig. 2). When sam-
ples acquired from resection were treated with FFPE, DNA
size was significantly shorter than FF samples (p < 0.001).
Compared to the formalin fixation procedure for the biop-
sied samples, the formalin fixation procedure after resection
was much more complex and time-consuming. For FF sam-
ples, no difference in DNA size was observed between biop-
sied samples and samples acquired from resection (p=0.141).
Storage duration was correlated with DNA fragment size for
FFPE tissues (p < 0.001) but not FF tissues (p=0.093). 
After sequencing tumor samples and removing duplicate
reads, the mean target coverage was 842 and was very 
important for mutation detection sensitivity. The mean target
coverage was correlated with the amount of DNA input and
the median DNA fragment size. When possible, 300 ng of
DNA was used for sequencing and when the DNA amount
was not sufficient, less than 300 ng of DNA was used. Mean
target coverage was reduced when less than 300 ng of DNA
(p < 0.001) or shorter median DNA fragment size (< 350 bp,
p < 0.001) was used (S7 Table, S8 and S9 Figs.).
Tissue quality was found to vary among the five institutes
(Table 1, S10 Fig.). Because different types of tissues were col-
lected (e.g., FF vs. FFPE; biopsy vs. resection) among the 
institutes, it was difficult to do a direct comparison. How-
ever, when the percentages of samples that passed our inclu-
sion criteria were compared, the test quality was remarkably
worse in tissues from Institute B. Firth’s bias-reduced logistic
regression model was carried out using sample conditions
and overall test failure status to examine the effect of each
variable (Fig. 3). The overall test failure rate was higher when
FFPE tissue (OR, 0.19; p < 0.001), biopsied sample (OR, 0.17;
p < 0.001), or samples with a long storage time (OR, 0.86/yr;
p=0.005) were used (S11 Table). Although DNA length was
longer in biopsied samples, the higher test failure rate 
observed was likely due to a lower DNA yield. The test fail-
ure rate was not significantly different among different
tumor types, but a significant difference in the test failure
rate of samples from different institutes was observed (insti-
tute C vs. E; OR, 0.07; p=0.014).
Quality of test influenced the detection of variants if the
mean coverage is extremely low. The number of detected
SNVs decreased when the mean target coverage was lower
Cancer Res Treat. 2019;51(1):211-222
Institute
A B C D E
Tissue preparation (%)
FF 0 0 1.2 63.2 55.0
FFPE 100 100 98.8 36.8 45.0
Specimen type (%)
Biopsy 1.3 0 48.3 74.8 100
Resection 98.7 100 51.7 25.2 0
Tissue storage time (yr) 4.6±0.6 4.5±0.4 2.6±2.8 0.3±0.9 0.1±0.03
DNA yield (µg) 2.1±1.7 0.7±0.6 1.1±1.5 0.5±0.2 1.9±1.6
DNA median size (kb) 1.1±0.5 1.1±0.6 4.7±5.8 25.9±21.2 20.9±25.1
Mean target coverage 465±167 285±168 774±254 928±185 888±309
Overall pass rate (%) 88.6 56.1 80.2 92.7 100
Table 1. Quality measures and pass rate among different institutes
FF, fresh frozen; FFPE, formalin-fixed, paraffin embedded.
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than 100 (p < 0.001). However, the number of detected
CNAs increased when the mean target coverage was lower
than 100 (p < 0.001) (S12 Fig.). The mean coverage did not
affect the detection rate of clinically important variant, EGFR
T790M.
3. Mutation landscape
We investigated the significantly mutated genes per tumor
type and compared them to TCGA data. In our NSCLC sam-
ples (n=401), significantly mutated genes were EGFR (q <
0.001), PRKDC (q < 0.001), TP53 (q < 0.001), FGF23 (q < 0.001),
KRAS (q < 0.001), EPHB6 (q=0.002), and RB1 (q=0.003) 
(S13 Fig.). Except for PRKDC, FGF23, and EPHB6 these genes
were significantly mutated in TCGA data [4,12]. Other genes
that were significantly mutated in NSCLC in the TCGA data
(ARID1A, KEAP1, CDKN2A, PIK3CA, NKX2-1, SMAD4, and
PTEN) were also frequently mutated in this study. Signifi-
cantly amplified regions included the 7p11.2 region which
contains the EGFR and HGF genes (q < 0.001), the 14q13.3 
region which contains the FOXA1, NFKBIA, and NKX2-1
gene (q < 0.001), the 12q15 region which contains the BTG1
and MDM2 genes (q < 0.001), the 11q13.3 region which con-
tains the CCND1, FGF4, MEN1, and FGF19 genes (q < 0.001),
the 17q12 region which contains the ERBB2, RARA, CDK12,
CCNE1, CEBPA, and MEF2B genes (q < 0.001), the 20q13.2
region which contains the AURKA, ZNF217 and NCOA3
genes (q < 0.001), and the 12q14.1 region which contains the
CDK4, ERBB3, and MDM2 genes (q=0.004), and 3q27.1 
region which contains the PIK3CA, SOX2, MAP3K13, and
KLHL6 genes (q=0.035), and the 8q21.3 region which contains
RUNX1T1 and MYC genes (q=0.092). Significantly deleted
regions were the 9p21.3 region which contains the CDKN2A
and CDKN2B genes (q < 0.001) (S14 Fig.). 
In our SCLC samples (n=60), significantly mutated genes
were TP53 (q < 0.001), RB1 (q < 0.001), FGF23 (q=0.005), and
FANCM (q=0.060) (S15 Fig.). Prior studies have shown 
detection of TP53 and RB1 inactivation in nearly all SCLC
samples when whole genome sequencing was carried out
[13]. The mutation frequency of these genes observed in this
study, 88% for TP53 and 75% for RB1, was similar to other
exome sequencing data [14]. The 4q12 region that contains
the KDR, KIT, and PDGFRA genes (q=0.024) and the 19q12
region that contains the CCNE1, CEBPA, and MEF2B genes
(q=0.026) were also significantly amplified in our SCLC sam-
ples (q=0.023) (S16 Fig.). 
In the stomach cancer samples (n=119), significantly 
mutated genes were TP53 (q < 0.001), CDH1 (q < 0.001), and
ARID1A (q=0.041) (S17 Fig.). Other frequently altered genes
that were significantly mutated in stomach cancer in the
TCGA data [15] were KRAS, SMAD4, ERBB2, PIK3CA,
CTNNB1 and APC. Significantly amplified regions in our
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Fig. 3.  Multivariate analysis of the effect of sample condition on QC pass. QC fails were more frequently observed particularly
in biopsied specimens or specimens with long storage time. In the forest plot, odds ratios (ORs) were described in log scale.
When the confidence interval does not contain 1.00, the p-value is less than 0.05. FF, fresh frozen; FFPE, formalin-fixed, paraf-
fin embedded.
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Fig. 4.  Proportion of patients having actionable variants of certain genes in this cohort. Most frequently observed mutations
in each cancer types were EGFR mutation in non-small cell lung cancer (NSCLC), RICTOR amplification in small cell lung
cancer (SCLC), KRAS mutation in colorectal cancer (CRC), and PIK3CA mutation in breast cancer and stomach cancer. Sig-
nificant proportion of actionable mutations were found in low frequency, showing long tail.
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samples were the 19q12 region which contains the CCNE1,
CEBPA, and MEF2B genes (q < 0.001), the 10q26.13 region
which contains the FGFR2 gene (q < 0.001), the 20q13.2 
region which contains the AURKA, ZNF217 and NCOA3
genes (q < 0.001), the 7p11.2 region which contains the EGFR,
HGF, and IKZF1 genes (q < 0.001), and the 17q12 containing
the ERBB2 and RARA genes (q=0.001). Significantly deleted
regions were the 19p13.2 region which contains the SMARCA4
gene (q=0.050) (S18 Fig.). 
In the CRC samples (n=23), significantly mutated genes
were APC (q < 0.001), KRAS (q < 0.001), TP53 (q < 0.001),
SMAD4 (q < 0.001), PIK3CA (q < 0.001), FBXW7 (q < 0.001),
and SOX9 (q=0.033). These genes were also significantly 
mutated in TCGA data [16] (S19 Fig.). The 12p13 region that
contains the CCND2, CHD4, FGF6, RAD52 and FGF23 genes
was significantly amplified (q=0.013) (S20 Fig.). 
In our breast cancer samples (n=25), the genes TP53 (q <
0.001), GATA3 (q < 0.001), and PIK3CA (q=0.014) were found
to be significantly mutated (S21 Fig.). Other frequently 
altered genes that were significantly mutated in breast cancer
in the TCGA data were CDH1, ERBB2, NF1, and MAP3K1.
Significantly amplified regions in our samples were the
17q12 region which contains the ERBB2, RARA, and CDK12
genes (q < 0.001) and the 11q13.3 region which contains the
CCND1, MEM1, and FGF19 genes (q=0.007) (S22 Fig.).
The TERT promoter region was included in the sequencing
panel used in this study. We found that a TERT promoter
mutation was present in 3% of NSCLCs, 5% of stomach can-
cers, 2% of CRCs, and 2% of breast cancers. Frequently 
altered sites were G>A substitutions at –124 bp (n=6) and 
–146 bp (n=3) upstream from the translation start site.
4. Actionable genetic alterations 
In this study, an actionable genetic alteration was defined
as a genomic variation that was a known drug target, regard-
less of tumor type. Here, 54.2% of the tested samples had one
or more actionable genetic alteration. The proportion of sam-
ples with actionable genetic variants was higher in NSCLC
(68%), CRC (52%), and breast cancer samples (52%) than in
stomach cancer (28%), SCLC (13%), and other cancer types
(28%) (Fig. 4, S23 Fig.). There were 25 genes with actionable
alterations; EGFR, KRAS and PIK3CA were the most fre-
quently altered actionable genes containing 72% of action-
able alterations. In NSCLC, 47% of samples had actionable
alterations in the EGFR gene, and 27% of samples had action-
able alterations in genes other than EGFR. Although action-
able alterations of EGFR, KRAS, BRAF, ALK, RICTOR, RET,
and ROS1 were mutually exclusive, some actionable alter-
ations of PIK3CA, ERBB2, MDM2, CDK4, FGFR1, NRAS, and
CTNNB1 coexisted with other actionable alterations (S24 Fig.).
Actionable alterations of EGFR were only present in NSCLC,
but actionable alterations of KRAS, PIK3CA, and ERBB2 were
present across almost every cancer type in our study. 
5. A case of personalized therapy using NGS study
A 36-year-old never-smoker woman was diagnosed with
lung adenocarcinoma and right upper lobectomy with adju-
vant chemotherapy was done. No EGFR and KRAS mutation
was detected at initial diagnosis. Two years after the surgery,
adenocarcinoma recurred at supraclavicular lymph node and
the patient received concurrent chemoradiotherapy. Two
years later, tumor progressed to involve trachea. Tracheal 
lesion was biopsied to perform fluorescence in situ hybri-
dization study for ALK, RET, ROS1 translocation. ALK tran-
slocation was detected and the patient is treated with crizo-
tinib. Airway lesion and mediastinal lymphadenopathy 
improved after crizotinib treatment. Eighteen months after
the therapy, size of mediastinal and intraabdominal lymph
node increased. Mediastinal lymph nodes was biopsied to
perform NGS study. ALK G1269A mutation was detected
with KIF5B/ALK fusion. The patient received ceritinib which
overcomes resistance to ALK G1269A mutation. Mediastinal
and intraabdominal lymph nodes disappeared after two
months of ceratinib therapy. After 16 months, the patient 
remains on treatment with no signs of tumor progression.
Discussion
In this study, we report our experience as a central bioin-
formatics laboratory determining the frequency of actionable
genomic alterations in over 1,000 tumor samples from five
different institutes. We found that 54% of our tested samples
had one or more actionable genetic alterations. A higher pro-
portion of actionable genetic variants was observed in
NSCLC (64%), CRC (52%), and breast cancer (52%) samples
compared to the other cancer types. These findings under-
score that numerous patients may benefit from clinical tumor
sequencing. Several, but not all, actionable genes can be
tested one at a time using conventional sequencing tech-
niques such as Sanger sequencing. In contrast, a high-through-
put panel sequencing can test all potential actionable genes
simultaneously which ultimately helps clinicians find thera-
peutic options that best fit each patient. It takes a lot of time
and specimens to test multiple genes sequentially. As a 
result, testing with multiplex platform has become common-
place in major cancer centers. We detected actionable alter-
ations that provide therapeutic benefit in both the major
tumor types in which genetic testing is frequently performed
as well as in rare types of cancer, although such alterations
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appeared to be less frequent in the rare cancers [17]. Thus,
high-throughput panel sequencing can also benefit patients
with rare cancers. Novel, flexible clinical trial designs (i.e.,
umbrella trials and basket trials), in which patients are 
assigned to investigational therapies based on their muta-
tional profile, have emerged and facilitated new targeted
therapeutic strategies [18]. It is anticipated that patients with
NGS-defined biomarkers will ultimately receive genomically
matched therapies that could result in improved clinical out-
comes [19]. Measuring the burden of nonsynonymous 
mutation has become important as it is the predictor of 
immunotherapy response in cancer patients [20]. NGS test
will also be utilized in predicting immunotherapy response.
The overall actionable mutation frequency in our study
(54%) was significantly higher than that observed in the 
Memorial Sloan Kettering Cancer Center (MSKCC)-study
using MSK-IMPACT (37%) [2]. There are three factors that
may have contributed to this difference. First, the proportion
of samples from NSCLC patients in our cohort was higher
than that in the MSKCC-study [2]. Second, EGFR mutation
in NSCLC patients has been reported to be more prevalent
in the Asian population and in the female populations [4,21].
Indeed, compared to the EGFR mutation frequency in NSC-
LC patients in the MSKCC cohort (24%), the frequency in our
cohort was much higher (47%), similar to previous reports
[2,21]. Third, MSK-IMPACT excluded KRAS mutations from
the actionable category, while we included them in our
analysis [2]. The combination of these three factors likely 
increased the actionable mutation frequency in our study.
The mutation burdens in this study were also somewhat
higher than the previously reported mutation rates [22,23].
As our target genes were enriched for cancer-related genes
and the samples sequenced at high coverage (> 800), the
mutation burden of our data is likely higher than that of
whole genome sequencing or whole exome sequencing data.
In comparison with the conventional sequencing methods,
one big hurdle in the implementation of NGS tests into rou-
tine practice can be the cost efficiency on the provider end.
Substantial setup costs are required for the computational 
infrastructure, such as a laboratory space for the cooling sys-
tem, electricity, fault recovery, a backup system, along with
IT support [7]. To improve the affordability and sustainabil-
ity of this technology, an alternative approach to current
practice needs to be considered. Souilmi et al. [24] suggested
that this bioinformatic bottlenecks could be overcome by
cloud-based computing. However, the possibility of expos-
ing sensitive personal genomic data while transferring and
sharing data raises privacy and ethical concerns. Even if
these issues are resolved by de-identification techniques, 
another challenge is the integration of multiple data sources
and the minimization of inter-laboratory data discrepancies
that can arise from differences in instruments, experimental
methods, sequencing instruments and analysis platforms.
Furthermore, the target regions differ substantially between
laboratories, which leads to challenges in the normalization
of the systemic biases, especially in copy number and RNA
expression data [25]. The use of different data analysis tools
by each laboratory results in a different output format. Merg-
ing these different outputs into one format is another obsta-
cle.
To overcome these challenges, we performed pan-cancer
panel sequencing using a centralized laboratory system
model [8]. This system allowed us to consistently sequence
tumor samples from different institutes and combine data
sets without adjusting their format. Within a centralized sys-
tem we needed to set appropriate tissue requirements for 
optimizing an NGS workflow [26]. Recently, several studies
have discussed the appropriate amount of DNA required for
successful sequencing [5,26-28]. Cho et al. [26] proposed that
more than five unstained slides (5 µm in thickness) for FFPE
biopsies and more than one unstained slide for FFPE resec-
tion specimens were adequate for a NGS. However, the min-
imum amount of DNA required for different NGS workflows
varies, and the amount of DNA extracted from one slide also
varies depending on the area and volume of the tumor tissue
[26,27]. Thus, it is difficult to predict the minimum number
of unstained slides and the exact DNA yield in clinical prac-
tice. To minimize test failures resulting from an insufficient
amount of DNA, we established our criterion: 10 unstained
slides for FFPE biopsies and two unstained slides for FFPE
resection specimens. Additionally, we found that for FFPE
samples, inadequate DNA quality was correlated with the
storage duration. As DNA in FFPE tissue blocks is likely to
be degraded during storage, we suggest that the storage 
duration should be considered and, if possible, controlled
when sequencing FFPE samples. It would be better to use
FFPE tissue blocks with storage duration less than 3 years to
ensure test quality. To use NGS study in clinics, it is impor-
tant to check if the sequencing covered all the important 
position. We used test results with mean target coverage
more than 200 only. Theoretically 200 coverage is required
to detect variants of allele fraction 10% with 99% sensitivity
[28].
To use NGS test in clinical practice, it should not take too
long for the test results to be produced. The duration of DNA
extraction to NGS reporting was 2-3 weeks with fast mode
[29]. We believe that this turn-around time is adequate for
patients to make timely therapeutic decisions. For longitudi-
nal monitoring of a patient’s actionable tumor mutations, it
is not always possible to collect recurring tumor specimens
by invasive methods. In those cases, sequencing circulating
tumor DNA (ctDNA) from plasma may be a viable alterna-
tive [30]. Several attempts have been made to apply this tech-
nique in clinical trials [31]. Once the accuracy of testing
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ctDNA improves, genome-matched therapy is likely to be
more widely practiced.
In conclusion, drawing on our experiences, we support the
use of an NGS workflow in a centralized laboratory system
model. We hope that our insight could help in the integration
of genomic data from different institutes and the understand-
ing of disease-gene relationships.
Electronic Supplementary Material
Supplementary materials are available at Cancer Research and
Treatment website (https://www.e-crt.org).
Conflicts of Interest
The authors declare that they have no conflicts of interests. This
research was mainly funded by Illumina Inc. (San Diego, CA, USA).
Acknowledgments
We thank Kirsten Curnow, Kristine Jinnett, and Mueller Amy, an
employee of Illumina Inc., for providing medical writing support.
This research was supported by a grant of the Korean Health Tech-
nology R&D Project through the Korea Health Industry Develop-
ment Institute, funded by the Ministry of Health & Welfare, Repub-
lic of Korea (HI13C2096 to W.Y.P., HI14C0072 to H.L.K.), and grant
from Ministry of Food and Drug Safety, Republic of Korea (16173-
MFDS004 to W.Y.P.).
Author Details
1Division of Hematology and Oncology, Department of Medicine,
Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, 2Department of Health Science and  Technology,
Samsung Advanced Institute of Health Science and Technology,
Sungkyunkwan University, Seoul, 3Samsung Genome Institute,
Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, 4Department of Internal Medicine, Seoul National
University Hospital, Seoul National University College of Medicine,
Seoul, 5Department of Internal Medicine, Korea University Anam
Hospital, Korea University College of Medicine, Seoul, 6Department
of Pathology, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, 7Division of Medical Oncology, Yonsei
Cancer Center, Yonsei University College of Medicine, Seoul, 
Departments of 8Colon & Rectal Surgery and 9Oncology, Asan Med-
ical Center, University of Ulsan College of Medicine, Seoul, 
10Department of Surgery, Seoul National University Hospital, Seoul
National University College of Medicine, Seoul, 11Department of
Thoracic and Cardiovascular Surgery, Seoul National University
Bundang Hospital, Seoul National University College of Medicine,
Seongnam, 12Department of Internal Medicine, Seoul St. Mary’s
Hospital, College of Medicine, The Catholic University of Korea,
Seoul, 13Department of Pathology, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, 14Department of Pathology,
Severance Hospital, Yonsei University College of Medicine, Seoul,
15Department of Pathology, Seoul National University Hospital,
Seoul National University College of Medicine, Seoul, 16Department
of Biochemistry and Molecular Biology, Seoul National University
College of Medicine, Seoul, 17Department of Microbiology, College
of Medicine, The Catholic University of Korea, Seoul, 18Department
of Medical Informatics, Pusan National University School of Medi-
cine, Yangsan, 19Department of Biochemistry, Ewha Womans Uni-
versity School of Medicine, Seoul, 20Department of Molecular Cell
Biology, Sungkyunkwan University School of Medicine, Seoul,
Korea
1. Meyerson M, Gabriel S, Getz G. Advances in understanding
cancer genomes through second-generation sequencing. Nat
Rev Genet. 2010;11:685-96.
2. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et
al. Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients. Nat Med.
2017;23:703-13.
3. Katsnelson A. Momentum grows to make 'personalized' med-
icine more 'precise'. Nat Med. 2013;19:249.
4. Cancer Genome Atlas Research Network. Comprehensive 
molecular profiling of lung adenocarcinoma. Nature. 2014;511:
543-50.
5. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing
SR, He J, et al. Development and validation of a clinical cancer
genomic profiling test based on massively parallel DNA 
sequencing. Nat Biotechnol. 2013;31:1023-31.
6. Cho YS, Kim H, Kim HM, Jho S, Jun J, Lee YJ, et al. An ethni-
cally relevant consensus Korean reference genome is a step 
towards personal reference genomes. Nat Commun. 2016;7:
13637.
7. Schadt EE, Linderman MD, Sorenson J, Lee L, Nolan GP. Com-
putational solutions to large-scale data management and
analysis. Nat Rev Genet. 2010;11:647-57.
8. Hynes SO, Pang B, James JA, Maxwell P, Salto-Tellez M. Tis-
sue-based next generation sequencing: application in a uni-
versal healthcare system. Br J Cancer. 2017;116:553-60.
References
VOLUME 51 NUMBER 1 JANUARY 2019  221
Cancer Res Treat. 2019;51(1):211-222
9. Shin HT, Choi YL, Yun JW, Kim NK, Kim SY, Jeon HJ, et al.
Prevalence and detection of low-allele-fraction variants in clin-
ical cancer samples. Nat Commun. 2017;8:1377.
10. Lee S, Seo J, Park J, Nam JY, Choi A, Ignatius JS, et al. Korean
Variant Archive (KOVA): a reference database of genetic vari-
ations in the Korean population. Sci Rep. 2017;7:4287.
11. Guyard A, Boyez A, Pujals A, Robe C, Tran Van Nhieu J, 
Allory Y, et al. DNA degrades during storage in formalin-fixed
and paraffin-embedded tissue blocks. Virchows Arch. 2017;
471:491-500.
12. Cancer Genome Atlas Research Network. Comprehensive 
genomic characterization of squamous cell lung cancers. 
Nature. 2012; 489:519-25.
13. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Com-
prehensive genomic profiles of small cell lung cancer. Nature.
2015;524:47-53.
14. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D,
Kasper LH, et al. Integrative genome analyses identify key 
somatic driver mutations of small-cell lung cancer. Nat Genet.
2012;44:1104-10.
15. Cancer Genome Atlas Research Network. Comprehensive 
molecular characterization of gastric adenocarcinoma. Nature.
2014;513: 202-9.
16. Cancer Genome Atlas Network. Comprehensive molecular
characterization of human colon and rectal cancer. Nature.
2012;487:330-7.
17. Lim SM, Yoo JE, Lim KH, Meng Tai DW, Cho BC, Park YN.
Rare incidence of ROS1 rearrangement in cholangiocarcinoma.
Cancer Res Treat. 2017;49:185-92.
18. Menis J, Hasan B, Besse B. New clinical research strategies in
thoracic oncology: clinical trial design, adaptive, basket and
umbrella trials, new end-points and new evaluations of 
response. Eur Respir Rev. 2014;23:367-78.
19. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao
J, et al. Prospective comprehensive molecular characterization
of lung adenocarcinomas for efficient patient matching to 
approved and emerging therapies. Cancer Discov. 2017;7:596-
609.
20. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V,
Havel JJ, et al. Cancer immunology: mutational landscape 
determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science. 2015;348:124-8.
21. Lee B, Lee T, Lee SH, Choi YL, Han J. Clinicopathologic char-
acteristics of EGFR, KRAS, and ALK alterations in 6,595 lung
cancers. Oncotarget. 2016;7:23874-84.
22. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati
S, Biankin AV, et al. Signatures of mutational processes in
human cancer. Nature. 2013;500:415-21.
23. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al.
Mutational landscape and significance across 12 major cancer
types. Nature. 2013;502:333-9.
24. Souilmi Y, Lancaster AK, Jung JY, Rizzo E, Hawkins JB,
Powles R, et al. Scalable and cost-effective NGS genotyping in
the cloud. BMC Med Genomics. 2015;8:64.
25. Pfundt R, Del Rosario M, Vissers LE, Kwint MP, Janssen IM,
de Leeuw N, et al. Detection of clinically relevant copy-num-
ber variants by exome sequencing in a large cohort of genetic
disorders. Genet Med. 2017;19:667-75.
26. Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, et
al. Tissue recommendations for precision cancer therapy using
next generation sequencing: a comprehensive single cancer
center's experiences. Oncotarget. 2017;8:42478-86.
27. Austin MC, Smith C, Pritchard CC, Tait JF. DNA yield from
tissue samples in surgical pathology and minimum tissue 
requirements for molecular testing. Arch Pathol Lab Med.
2016;140:130-3.
28. Lee C, Bae JS, Ryu GH, Kim NK, Park D, Chung J, et al. A
method to evaluate the quality of clinical gene-panel sequenc-
ing data for single-nucleotide variant detection. J Mol Diagn.
2017;19:651-8.
29. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH,
Guebert K, Bredemeyer AJ, et al. Clinical next-generation 
sequencing in patients with non-small cell lung cancer. Can-
cer. 2015;121:631-9.
30. Alix-Panabieres C, Pantel K. Clinical applications of circulat-
ing tumor cells and circulating tumor DNA as liquid biopsy.
Cancer Discov. 2016;6:479-91.
31. Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM,
et al. Prospective blinded study of somatic mutation detection
in cell-free DNA utilizing a targeted 54-gene next generation
sequencing panel in metastatic solid tumor patients. Oncotar-
get. 2015;6:40360-9.
222 CANCER  RESEARCH  AND  TREATMENT
